Calamos Advisors »

Aeglea Biotherapeutics shares owned by Calamos Advisors

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Calamos Advisors from 13F filings

Historical chart of Calamos Advisors investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Calamos Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Calamos Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.0M 11k 88.78

More positions owned by Calamos Advisors

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Calamos Etf Tr Tax Awa Coll Etf
Western Digital Corp Note 3.000%11/1 (Principal)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Micron Technology (MU)
Eli Lilly & Co. (LLY)
Alphabet Cap Stk Cl C (GOOG)
Advanced Micro Devices (AMD)

View all positions for Calamos Advisors

Top funds holding Aeglea Biotherapeutics

FMR
BlackRock
Perceptive Advisors
Rtw Investments
Paradigm Biocapital Advisors
Vanguard Capital Management
VR Adviser
Driehaus Capital Management
State Street Corporation
Geode Capital Management
Vanguard Portfolio Management
Jupiter Topco
TCG Crossover Management
Tang Capital Management
Bank of America Corporation

View all funds holding Aeglea Biotherapeutics